NCT05420077 is a Phase 1 clinical trial of RVM-V001 10 µg in Infectious Disease, sponsored by RVAC Medicines (US), Inc..

Who is sponsoring NCT05420077?

NCT05420077 is sponsored by RVAC Medicines (US), Inc..

What drugs are being tested in NCT05420077?

Interventions in NCT05420077: RVM-V001 10 µg, RVM-V001 30 µg, RVM-V001 60 µg.

What condition does NCT05420077 study?

NCT05420077 studies Infectious Disease, COVID-19.

Is NCT05420077 still recruiting?

NCT05420077 is currently terminated. Last updated 27 June 2023.

Last reviewed 2023-06-27 · How we verify

NCT05420077

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273

Terminated Phase 1 Last updated 27 June 2023

What this trial tests

Phase 1 trial testing RVM-V001 10 µg in Infectious Disease in 13 participants. Terminated before completion.

Timeline

12 September 2022

Primary endpoint
2 June 2023

2 June 2023

Quick facts

Lead sponsor	RVAC Medicines (US), Inc.
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	none
Primary purpose	prevention
Enrollment	13
Start date	12 September 2022
Primary completion	2 June 2023
Estimated completion	2 June 2023
Sites	2 locations across Australia

Drugs / interventions tested

RVM-V001 10 µg — full drug profile →
RVM-V001 30 µg — full drug profile →
RVM-V001 60 µg — full drug profile →

Conditions studied

Infectious Disease — all drugs for Infectious Disease →
COVID-19 — all drugs for COVID-19 →

Sponsor

RVAC Medicines (US), Inc. — full company profile →

Who can join

Adults 18 to 65, any sex, with Infectious Disease or COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase 1, open-label, dose-escalation study to evaluate the safety, tolerability, and immunogenicity of RVM-V001 administered as a single intramuscular injection in healthy adults. Three dose levels will be evaluated, with progression from low- to high-dose level based on the assessment of safety and tolerability. The study will be conducted at one or more sites in Australia.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

mRNA vaccines: A novel weapon to control infectious diseases.
Tian Y, Deng Z, Yang P. · · 2022 · cited 14× · PMID 36267192 · DOI 10.3389/fmicb.2022.1008684
Race with virus evolution: The development and application of mRNA vaccines against SARS-CoV-2.
Lee KM, Lin SJ, Wu CJ, Kuo RL. · · 2023 · cited 9× · PMID 36642222 · DOI 10.1016/j.bj.2023.01.002
Research progress of mRNA vaccines for infectious diseases.
Zhang Z, Du J, Zhang D, Han R, et al · · 2025 · cited 5× · PMID 40847375 · DOI 10.1186/s40001-025-03060-x
Comparative analysis of the effectiveness difference of SARS-COV-2 mRNA vaccine in different populations in the real world: A review.
Cai S, Chang C, Zhang X, Qiao W. · · 2023 · cited 4× · PMID 37653835 · DOI 10.1097/md.0000000000034805

Verify or expand the search:

Other recruiting trials for Infectious Disease

Currently open trials in the same condition.

NCT06426147 — L-citrulline to Improve Adverse Outcomes in Admitted Children (EChiLiBRiST, Clinical Trial 2, Inpatients) · NA · recruiting
NCT07069400 — An International Observational Study of Adults With Acute Infection · recruiting
NCT06422338 — A Rapid Triage Test to Improve Risk-stratification of Febrile Children (EChiLiBRiST, Clinical Trial 1, Outpatients) · NA · recruiting
NCT06510699 — Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial · Phase 2 · recruiting
NCT05972772 — Rickettsia Clearance Study · Phase 2, PHASE3 · recruiting

Other RVAC Medicines (US), Inc. trials

Trials by the same sponsor.

NCT05788185 — Safety & Immunogenicity of RVM-V001/RVM-V002 or RVMV001+RVMV002 (Co Administered as Separate Injections) in Healthy Indi · Phase 1, PHASE2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05420077 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by RVAC Medicines (US), Inc.
Last refreshed: 27 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05420077.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing